We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Warns Allergan Over Postmarket Study of Breast Implants
FDA Warns Allergan Over Postmarket Study of Breast Implants
Allergan failed to comply with post-approval study requirements for its Natrelle silicone-filled breast implants, the FDA said in a warning letter to the Irvine, California-based company.
To View This Article:
Login
Subscribe To International Devices & Diagnostics Monitor